Drug · Small Molecule

Omacetaxine Mepesuccinate

CI-DRUG-00000418Explore in graph →NCIt C1127 CHEMBL46286 CIViC Approved

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	15	10	6	34	—	—	1994-09
Leukemia	Phase3	Phase 3	10	6	5	27	—	—	1994-09
Malignant Prostate Neoplasm	Phase2	Phase 2	1	1	0	1	—	—	Apr 20, 2025
Non-Hodgkin Lymphoma	Phase2	Phase 2	1	0	0	1	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 T315I + ABL1 Fusion2
Omacetaxine Mepesuccinate

Clinical trials

Trials with this intervention (34)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–34 of 34 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07813390	Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML)	enrolling by invitation	Phase 2	73	Guangdong Second Provincial General HospitalOTHER	1	Sep 10, 2026	clinicaltrials
NCT07131059	MRD-positive AML Clinical Study	recruiting

Molecule

Record

Kind: Small Molecule
Mechanism: Protein synthesis inhibitor
Aliases: Ceflatonin, Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI), CGX-635, HHT, Homoharringtonin, Homoharringtonine, HOMOHARRINGTONINE, Mepesuccinate d'omacetaxine, Mepesuccinato de omacetaxina, Myelostat, NSC-141633, Omacetaxine Mepesuccinate, Omapro, Synribo

Data updated 23 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.